(To unsubscribe at anytime, see bottom of newsletter)
VCEL - Vericel Corporation
Total Revenues of $14.7 Million Reported for the Fourth Quarter
Vericel Reports Fourth-Quarter and Year-End 2014 Financial Results
(See news below)
Read Full Article Here: http://finance.yahoo.com/news/vericel-reports-fourth-quarter-end-200100825.html
Company Overview
Website: http://www.vcel.com/
Developing Patient Specific Expanded Cellular Therapies
Vericel Corporation (formerly Aastrom Biosciences) is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two cell therapy products in the United States, Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM).
Product Portfolio http://vcel.com/product-portfolio/
Website: http://www.vcel.com/
Developing Patient Specific Expanded Cellular Therapies
Vericel Corporation (formerly Aastrom Biosciences) is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two cell therapy products in the United States, Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM).
Product Portfolio http://vcel.com/product-portfolio/
GlobeNewswire (Mon, Mar23)
Vericel Reports Fourth-Quarter and Year-End 2014 Financial Results
http://finance.yahoo.com/news/vericel-reports-fourth-quarter-end-200100825.html
GlobeNewswire (Wed, Mar 18)
Vericel to Present at Canaccord Genuity and ARM Investor Conferences
http://finance.yahoo.com/news/vericel-present-canaccord-genuity-arm-125149778.html
Zacks Small Cap Research (Thu, Feb 5)
Why Vericel Shares Will Double In 2015
http://finance.yahoo.com/news/vcel-why-vericel-shares-double-190000765.html
GlobeNewswire (Thu, Jan 29)
Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
http://finance.yahoo.com/news/vericel-completes-patient-enrollment-phase-134500845.html
Marketwired (Wed, Jan 7)
Vericel Corporation Names Three New Board Members
http://finance.yahoo.com/news/vericel-corporation-names-three-board-134500916.html
Contact
Vericel Corporation
64 Sidney Sreet
Cambridge, MA 02139
United States - Map
Phone: 617-252-7999
Fax: 617-252-7550
Website: http://www.aastrom.com
Disclaimer
Manic Stock Alerts has not been compensated for VCEL
http://doiop.com/ManicDisclaimer
No comments:
Post a Comment